Status:
UNKNOWN
Oral Selenium Therapy for the Prevention of Mucositis
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Mucositis
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Selenium as an antioxidant and anti-inflammatory agent could be effective in prevention of mucositis induced by chemotherapy and radiotherapy. Other agents such as vitamin E, Zinc sulfate, amifostine,...
Detailed Description
Patients with AML or ALL diagnosis, candidates for high dose chemotherapy with stem cell transplantation will be screened for enrollment in the study. Patients will be randomized in two groups with b...
Eligibility Criteria
Inclusion
- Patients with AML or ALL undergoing high dose chemotherapy with stem cell transplantation
- Adequate renal and hepatic function
Exclusion
- Taking selenium supplement before admission
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT01432873
Start Date
June 1 2011
End Date
December 1 2012
Last Update
June 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology-Oncology & SCT Research Center
Tehran, Iran